Human trials of first breast cancer vaccine begin

Advances in medicine continue, this time researchers from the Cleveland Clinic announced that they will begin phase I of the clinical trials in humans of the first breast cancer vaccine.

In a statement they detailed that for the study of the vaccine they will be enrolled 18 to 24 women diagnosed with breast cancer triple negative (TNBC), which is the most aggressive and deadly form of the disease.

The trial will be carried out in association with Anixa Biosciences, based in San José, California, and they will be in charge of determining the safety and favorable dose of the human vaccine.

It may interest you: Daniela Romo seeks to raise awareness about the arrest of breast cancer | VIDEO

“The vaccine aims to provide immunological protection against emerging breast tumors related to α-lactalbumin,” said Dr. Budd, an oncologist at the Taussig Cancer Institute.

In December of last year the Food and Drug Administration (FDA) approved the vaccine for use in clinical trials, and it is now expected to be developed in September 2022.

How does the vaccine work?

Dr. Tuohy, principal inventor of the vaccine and investigator in the Department of Inflammation and Immunity, explained that the vaccines They consist of two parts: the target antigens and adjuvants.

“At a basic level, adjuvants help stimulate the immune response to respond to the target antigen. When ready, we believe that the immune system can destroy breast cancer cells as they arise so that cancer cells do not have a chance to develop into mature tumors that are difficult to treat, ”explained Dr. Tuohy in the statement.

It may interest you: IMSS gave Rosa María treatment for breast cancer, who received a second chance

The vaccine targets the a-lactalbumin protein, which is found in the mammary glands of women during the last part of pregnancy and during lactation. The protein is “withdrawn” from expression in aging tissues, and the only other time the protein is expressed is when a woman develops TNBC, they explain.

It was in the preclinical work, published in 2010 in the journal Nature Medicine, when researchers found that a-lactalbumin vaccination was safe and effective in preventing breast cancer in mice.


Day Against Breast Cancer: Writer points out challenges to face fear of treatment

Breast Cancer: How Is A Self-Exam Performed?

IPN makes progress in early detection of breast cancer

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *